https://orcid.org/0000-0002-9983-5934
References
- Population fact sheets: Spain (2023). https://gco.iarc.fr/today/data/factsheets/populations/724-spain-fact-sheets.pdf
- González Del Alba A , Méndez-VidalMJ, VazquezSet al. SEOM clinical guidelines for the treatment of advanced prostate cancer (2020). Clin. Transl. Oncol.23(5), 969–979 (2021).
- Halabi S , KellyWK, MaHet al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J. Clin. Oncol.34(14), 1652–1659 (2016).
- Xie W , ReganMM, BuyseMet al. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J. Clin. Oncol.35(27), 3097–3104 (2017).
- Hussain M , FizaziK, SaadFet al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med.378(26), 2465–2474 (2018).
- Smith MR , SaadF, ChowdhurySet al. Apalutamide treatment and metastasis-free survival in prostate cancer. N. Engl. J. Med.378(15), 1408–1418 (2018).
- Smith MR , SaadF, OudardSet al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J. Clin. Oncol.31(30), 3800–3806 (2013).
- Tomaszewski EL , MoiseP, KrupnickRNet al. Symptoms and impacts in non-metastatic castration-resistant prostate cancer: qualitative study findings. Patient10(5), 567–578 (2017).
- Mateo J , FizaziK, GillessenSet al. Managing nonmetastatic castration-resistant prostate cancer. Eur. Urol.75(2), 285–293 (2019).
- Fizazi K , ShoreN, TammelaTLet al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med.380(13), 1235–1246 (2019).
- Fizazi K , SmithMR, TombalB. Clinical development of darolutamide: a novel androgen receptor antagonist for the treatment of prostate cancer. Clin. Genitourin. Cancer16(5), 332–340 (2018).
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer (2023). https://uroweb.org/guideline/prostate-cancer/
- Smith MR , ShoreN, TammelaTLet al. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial. Eur. J. Cancer154, 138–146 (2021).
- Moilanen AM , RiikonenR, OksalaRet al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci. Rep.5, 12007 (2015).
- Zurth C , SandmanS, TrummelD, SeidelD, NubbemeyerR, GieschenH. Higher blood-brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography. J. Clin. Oncol.37(Suppl. 7), 156 (2019).
- Fizazi K , ShoreN, TammelaTLet al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N. Engl. J. Med.383(11), 1040–1049 (2020).
- Uemura H , MatsushimaH, KobayashiKet al. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial. Int. J. Clin. Oncol.26(3), 578–590 (2021).
- Advanced prostate cancer: AUA/ASTRO/SUO guideline (2023). https://www.auanet.org/documents/Guidelines/PDF/Advanced%20Prostate%20Cancer%20Guideline.pdf
- Parker C , CastroE, FizaziKet al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.31(9), 1119–1134 (2020).